RT Journal Article
SR Electronic
T1 Rebound in asthma exacerbations following relaxation of COVID-19 restrictions: a longitudinal population-based study (COVIDENCE UK)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.01.22279473
DO 10.1101/2022.09.01.22279473
A1 Tydeman, Florence
A1 Pfeffer, Paul E
A1 Vivaldi, Giulia
A1 Holt, Hayley
A1 Talaei, Mohammad
A1 Jolliffe, David A
A1 Davies, Gwyneth A
A1 Lyons, Ronan A
A1 Griffiths, Christopher J
A1 Kee, Frank
A1 Sheikh, Aziz
A1 Shaheen, Seif O
A1 Martineau, Adrian R
YR 2022
UL http://medrxiv.org/content/early/2022/09/02/2022.09.01.22279473.abstract
AB Background The imposition of restrictions on social mixing early in the COVID-19 pandemic was followed by a reduction in asthma exacerbations in multiple settings internationally. Temporal trends in social mixing, incident acute respiratory infections (ARI) and asthma exacerbations following relaxation of COVID-19 restrictions have not yet been described.Methods We conducted a population-based longitudinal study in 2,312 UK adults with asthma between November 2020 and April 2022. Details of face covering use, social mixing, incident ARI and moderate/severe asthma exacerbations were collected via monthly on-line questionnaires. Temporal changes in these parameters were visualised using Poisson generalised additive models. Multilevel logistic regression was used to test for associations between incident ARI and risk of asthma exacerbations, adjusting for potential confounders.Results Relaxation of COVID-19 restrictions from April 2021 coincided with reduced face covering use (p<0.001), increased frequency of indoor visits to public places and other households (p<0.001) and rising incidence of COVID-19 (p<0.001), non-COVID-19 ARI (p<0.001) and moderate/severe asthma exacerbations (p=0.007). Incident non-COVID-19 ARI associated independently with increased risk of asthma exacerbation (adjusted odds ratio 5.75, 95% CI 4.75 to 6.97) as did incident COVID-19, both prior to emergence of the omicron variant of SARS-CoV-2 (5.89, 3.45 to 10.04) and subsequently (5.69, 3.89 to 8.31).Conclusions Relaxation of COVID-19 restrictions coincided with decreased face covering use, increased social mixing and a rebound in ARI and asthma exacerbations. Associations between incident ARI and risk of moderate/severe asthma exacerbation were similar for non-COVID-19 ARI and COVID-19, both before and after emergence of the SARS-CoV-2 omicron variant.Funding Barts Charity, UKRICompeting Interest StatementRAL declares membership of the Welsh Government COVID-19 Technical Advisory Group. AS is a member of the Scottish Government COVID-19 Advisory Group and its Standing Committee on Pandemics. He is also a member of the UK Government NERVTAG Risk Stratification Subgroup. All other authors declare that they have no competing interests.Funding StatementThis study was supported by a grant from Barts Charity to ARM and CJG (ref MGU0466). The work was carried out with the support of BREATHE - The Health Data Research Hub for Respiratory Health in partnership with SAIL Databank. BREATHE is funded by UK Research and Innovation [ref MC_PC_19004 to AS] and delivered through Health Data Research UK. MT is supported by a grant from the Rosetrees Trust and The Bloom Foundation (ref: M771).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Leicester South Research Ethics Committee, UK, gave ethical approval for this work (ref 20/EM/0117).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors, subject to terms of ethical approval.